Panayiotis P Constantinides
Biopharmaceutical & Drug Delivery Consulting, LLC, USA
Dr. Panayiotis (Panos) P. Constantinides is the President of Biopharmaceutical & Drug Delivery Consulting, LLC and Affi liated Professor of Biopharmaceutical Sciences at Roosevelt University, College of Pharmacy in Schaumburg, Illinois, with 25 years of experience in drug delivery and pharmaceutical development. He received a University Diploma in Chemistry from Athens University in 1977 and PhD in Biochemistry from Brown University in 1983. He was a postdoctoral fellow in the Pharmacology Department and Associate Research Scientist in the Comprehensive Cancer Center of Yale University School of Medicine (1983-1987). Past industrial positions held included: Vice President of R&D with DOR Biopharma and Morton Grove Pharmaceuticals (2001-2004), Director of Research at SONUS Pharmaceuticals (1997-2000) and from 1987 to 1997 a number of R&D positions of increasing responsibilities with LipoGen, SmithKline Beecham Pharmaceuticals and Abbott Laboratories. In addition, he serves as scientifi c advisor in early stage companies and contract research organizations. He has held adjunct faculty appointments with the Pharmaceutics Department of Washington University in Seattle, WA and the Department of Biochemistry of the University of Tennessee, in Knoxville, TN. He is inventor in 33 patents and patent applications, has authored more than 130 publications and has been invited speaker at many national and international conferences, biotech/pharma companies and universities. Dr. Constantinides is AAPS Fellow, current Chair of the AAPS Formulation Design and Development (FDD) Section and Past Chair of the Lipid-Based Drug Delivery Systems and the Nanotechnology Focus Groups.
There have been major advances and achievements in the use of nanoparticles for parenteral drug delivery and targeting especially for cancer drugs and biologics. Of particular interest are drug nanodispersions and include, liposomes, nanoemulsions, solid lipid nanoparticles, polymeric micelles, dendrimers, nanocrystals and nanosuspensions. Directing therapeutics to intracellular targets and selectively killing disease cells is the primary driving force behind the rapid evolution of nanoparticle-based approaches. A brief overview of nanoparticle design, manufacturing, characterization and in vitro/in vivo assessment, including Quality-by-Design (QbD) aspects, will be discussed during the first part of the talk. Case studies will then be presented with parenteral small molecules, approved drugs or New Molecular Entities (NMEs) employing nanoemulsions, liposomes, polymeric micelles and solid lipid nanoparticles. Improvements in the manufacturing methods and better understanding of the factors controlling stability will certainly expand the use of nanodispersions in parenteral drug
Speaker PPTsDownload PPT